Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 265Leukemia, Lymphocytic, Chronic, B-Cell 66Lymphoma, Large B-Cell, Diffuse 60Neoplasms, Plasma Cell 50Lymphoma, Follicular 45Lymphoma, Mantle-Cell 42Lymphoma 41Recurrence 38Lymphoma, B-Cell, Marginal Zone 31Leukemia 30Leukemia, Myeloid, Acute 27Lymphoma, B-Cell 19Lymphoma, Non-Hodgkin 17Myelodysplastic Syndromes 16Waldenstrom Macroglobulinemia 15Smoldering Multiple Myeloma 13Hodgkin Disease 13Lymphoma, T-Cell, Peripheral 12Neoplasms 11Lymphoma, T-Cell 9Prostatic Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, T-Cell, Cutaneous 8Immunoglobulin Light-chain Amyloidosis 8Burkitt Lymphoma 8Sezary Syndrome 7Neoplasm, Residual 7Mycosis Fungoides 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Plasma Cell 6

Interventions

Rituximab 2CT-P10 2prednylidene 1pembrolizumab 1deltacortene 1Vincristine 1Prednisone 1Lenalidomide 1Doxorubicin 1Cyclophosphamide 1ALX148 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Composite Lymphoma × Lenalidomide × Clear all
NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
47 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡